scholarly journals Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations

2018 ◽  
Vol Volume 11 ◽  
pp. 41-51 ◽  
Author(s):  
Laia Sans-Atxer ◽  
Dominique Joly
2017 ◽  
Vol 37 (4) ◽  
pp. 384-388 ◽  
Author(s):  
Sana Khan ◽  
Anna Giuliani ◽  
Carlo Crepaldi ◽  
Claudio Ronco ◽  
Mitchell H. Rosner

End-stage renal disease secondary to autosomal dominant poly-cystic kidney (ADPKD) is a common issue worldwide. Peritoneal dialysis (PD) is a reasonable option for renal replacement therapy for these patients and should not be withheld due to concerns that the patient may not tolerate the fluid volumes in the peritoneal cavity. This review covers the existing data on the outcomes and complications associated with the use of PD in the polycystic kidney disease patient. In general, PD is well tolerated and outcomes in ADPKD patients are equivalent to or better than other patient groups.


Nephron ◽  
1997 ◽  
Vol 75 (1) ◽  
pp. 109-111 ◽  
Author(s):  
Piero Dionisio ◽  
Adalberto Sessa ◽  
Ferruccio Conte ◽  
Roberto Bergia ◽  
Emanuele Stramignoni ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document